Institutional Outcomes following Total Pancreatectomy and Islet Autotransplantation in Children by Sekoulopoulos, Stephen P
Valparaiso University
ValpoScholar
Symposium on Undergraduate Research and
Creative Expression (SOURCE) Office of Sponsored and Undergraduate Research
Spring 5-3-2018
Institutional Outcomes following Total




Follow this and additional works at: https://scholar.valpo.edu/cus
This Poster Presentation is brought to you for free and open access by the Office of Sponsored and Undergraduate Research at ValpoScholar. It has been
accepted for inclusion in Symposium on Undergraduate Research and Creative Expression (SOURCE) by an authorized administrator of ValpoScholar.
For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.
Recommended Citation
Sekoulopoulos, Stephen P., "Institutional Outcomes following Total Pancreatectomy and Islet Autotransplantation in Children"
(2018). Symposium on Undergraduate Research and Creative Expression (SOURCE). 731.
https://scholar.valpo.edu/cus/731
Institutional Outcomes following Total Pancreatectomy with Islet 
Autotransplantation in Children 
Stephen Sekoulopoulos and Dr. Jaimie Nathan 
Cincinnati Children’s Hospital Division of  Pediatric General and Thoracic Surgery 
Aim 
• To review our institutional outcomes following total pancreatectomy and islet 
autotransplantation for debilitating acute recurrent (ARP) and chronic pancreatitis 
(CP) in children. 
Background 
• Chronic pancreatitis is a progressive fibroinflammatory injury that can result in 
endocrine and/or exocrine insufficiency, as well as in severe pain and impaired 
quality of life. 
•The fibrotic pancreas is removed while the insulin-producing islets are isolated and 
transplanted back into the patient, usually into the liver via the portal vein.  
 
Figure 1: Total pancreatectomy 
Figure 2: Biliary and Alimentary 
Tract Reconstruction 
Figure 3: Islet 
Autotransplantation 
Methodology 
• 17 patients underwent pancreatectomy with islet autotransplantation between April 
2015 and April 2017 at Cincinnati Children’s Hospital. 
• Open, pylorus-preserving approach with accompanied splenectomy and 
gastrojejunostomy tube placement. 
• 16 total pancreatecomies and 1 subtotal pancreatectomy. 
• Islet isolation by enzymatic and mechanical digestion (Ricordi method). 
• Documented surgical complications, readmission, reoperations 90 days post-op.  
• Preoperative and postoperative opioid use was assessed, as was islet function. 
Results 
Table 1: Demographic Data 
Criteria Values (N = 17)  
Sex (female) 11 (65%) 
Age (years) 12.1 (4 - 17) 
Weight (kg) 53.6 (16.6 – 108.3) 
Height (cm) 150.2 (103 – 185.5) 
Acute Recurrent Pancreatitis (yes) 3 (18%) 
Chronic Pancreatitis (yes) 14 (82%) 
Preoperative Enteral Tube or TPN (#) 7 (41%) 
Visits for Pain 18 months prior to operation (#)  2.5 (0 – 6) 
ED visits 18 months prior to operation (#) 1.3 (0 – 6) 
Genetic mutations (yes) 14 (82%) 
PRSS1 6 (35%) 
SPINK1 5 (29%) 
CFTR 6 (35%) 
CTRC 0 (0%) 
Pancreas Divisum (yes) 8 (47%) 
Autoimmune Pancreatitis (yes)  1 (6%) 
Pancreatic Exocrine Insufficiency (yes) 8 (47%) 
Required Pre-Operative Insulin 1 (6%) 
Postop ICU Length of Stay (days) 10.4 (7 – 18) 
Total Length of Hospital Stay (days) 26.1 (19 – 36)  
Figure 4: Pre-Op and Post-Op 
Pain Management 
Figure 5: Patients Requiring 
Opioids Following TPIAT 
Type of Medication and Usage Time Following TPIAT (months) 
Table 2: Post-Operative Complications 
Complication Values (N = 17)  
Intra-Abdominal Bleeding 1 (6%) 
Upper GI Bleeding 1 (6%) 
Small Bowl Obstruction 1 (6%) 
Wound Infection 2 (12%) 
Portal Vein Thrombosis 0 (0%) 
Fluid Collection 3 (18%) 
Hypoglycemia 1 (6%) 
Table 3: Readmission and Reoperation following TPIAT 
Criteria Values (N = 17)  
Number of Patients Readmitted 6 (35%) 
Fever 1 (6%) 
Abdominal  or Other Non-Localized Pain 4 (24%) 
Enteral Tube Complications 2 (12%) 
Length of Readmission (days) 4.9 (2 - 12) 
Patients Returning to the OR 2 (12%) 
Exploratory Laparotomy  2 (12%) 
Patients Requiring an IR/Endo Procedure 6 (35%) 
Drainage of Intra-abdominal Fluid 3 (18%) 
PICC 2 (12%) 
C-Line Removal 2 (12%) 
EGD  1 (6%) 
GJ Tube Change 2 (12%) 
Therapeutic Procedure 2 (12%) 
Table 4: Islet Infusion and Insulin Use 
Criteria Values (N = 17)  
Total IEQ 330,326 (172,300 – 488,000) 
IEQ/kg 6,677 (3,992 – 14,242) 
Portal Vein Infusion 16 (94%) 
Peritoneal Cavity Infusion 1 (6%) 
Insulin Independent 4 (24%) 
Time on Insulin (months) 8 (4 – 16) 
Partial Graft Function 13 (76%) 
Conclusions 
• TPIAT is an important option in treatment of children with ARP/CP 
and is considered when maximal medical therapies and endoscopic 
approaches fail to relieve pain and to address complications. 
 
• Comprehensive multidisciplinary patient evaluation is critical to 
ensure optimal outcomes following TPIAT. 
 
• In appropriately selected children, TPIAT achieves durable pain 
relief and improves QOL with manageable glycemic control. 
